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Abstract: Sulfhemoglobinemia is a rare entity caused by irreversible sulfation of the heme moiety 
in haemoglobin to form sulfated haemoglobin (SulfHb) and has been caused by H2S arising from 
certain metabolites of drugs and bacterial infection. Clinical presentation is similar to that of 
methemoglobin (MetHb). Furthermore, it is often difficult to distinguish between the diagnosis of 
SulfHb from MetHb in arterial blood gas analysers due to the broad overlap in the optical density 
(OD) absorption spectra—that of SulfHb swamping the more distinct OD absorption shift seen with 
MetHb. The presence of SulfHb was suspected in a 73-year-old lady with low oxygen saturation 
(SaO2 ~75%), central cyanosis, and normal arterial oxygen partial pressure (pO2 ~12 kPa). Repeated 
arterial blood gas analysis on different systems returned error messages for MetHb quantification. 
There was an improvement in oxygen saturation and cyanosis after an exchange transfusion. A full 
OD spectrophotometry (500–700 nm) of the patient’s whole blood was suggestive of the presence of 
SulfHb, with a minor peak absorption at 620 nm. Matrix-assisted laser desorption ionization time-
of-flight mass spectrometry (MALDI-ToF MS) was undertaken on whole blood samples from the 
patient pre- and post-transfusion, alongside normal controls. These demonstrated the presence of 
SulfHb in the patient’s blood, identifying sulfur, sulfur monoxide, and sulfur dioxide bound to the 
heme moiety. This gave vital identification as to the cause of Hb sulfation, which was distinct from 
that previously reported. Levels fell after the exchange transfusion and were completely eradicated 
after the correct source, an Epsom Salts constipation tonic, was identified. MALDI-ToF mass 
spectrometry is a new, rapid, specific, and sensitive diagnostic test for rare hematological 
syndromes such as SulfHb. In addition, it can identify the specific compounds bound to heme. Here, 
we provide useful diagnostic evidence as to the source of SulfHb, which was via SO2 rather than the 
previously described H2S. 
Keywords: sulfated haemoglobin; MetHb, SulfHb diagnosis; mass spectrometry; MALDI-TOF MS; 
oxygen saturation; arterial blood gas analysers. 
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1. Introduction 
A 73-year-old lady presented with a short history of cyanosis following an overseas trip that 
included two long-haul flights. On examination she was found to have peripheral oxygen saturations 
of around 75% and cyanosis of her lips, tongue, and fingers, with otherwise normal examination 
findings. She was initially investigated for possible pulmonary embolism, which was excluded on 
computerised tomography pulmonary angiography. The patient underwent extensive investigation 
by the Cardiology and Respiratory services, with an ultimate exclusion of primary cardiac or 
respiratory pathology as the cause. Her oxygen saturation remained low and was deteriorating on 
repeated arterial blood gas sampling, despite normal PaO2 levels (around 12 kPa), and her arterial 
blood was observed to be chocolate brown in colour (see Figure 1); this did not change when mixed 
with 100% O2 in a syringe. Methemoglobin (MetHb) was suspected [1], but repeated error messages 
for MetHb quantification were returned by arterial blood gas machines made by different 
manufacturers in three separate hospitals.  
 
Figure 1. Photograph illustrating the color difference between the patient’s venesected blood (left) 
and a normal donor unit (right). 
She was referred to a haematologist for further investigation. Hemoglobin high-performance 
liquid chromatography (HPLC) and capillary electrophoresis test results were normal. An urgent 
referral to a National Reference Laboratory for detailed analysis of the patient’s hemoglobin, 
including sequencing of her globin genes, also returned normal results. Screening for paroxysmal 
nocturnal haemoglobinuria and glucose-6-phosphate dehydrogenase deficiency were negative. She 
was prescribed ascorbic acid 200 mg once daily for a working diagnosis of a possible methemoglobin 
reductase deficiency, which produced no change in her cyanosis. After a subsequent emergency room 
presentation with fast atrial fibrillation and dyspnoea, the patient underwent an exchange red cell 
transfusion in the absence of a definitive diagnosis. This resulted in a significant improvement in her 
symptoms; reduced cyanosis and increased her oxygen saturation but had to be repeated weekly.  
A literature review identified sulfated haemoglobin (SulfHb) as another potential cause of the 
patient’s clinical signs [2]. She gave a history of rheumatoid arthritis, migraines, and severe 
constipation, and potential sources of sulfur identified among her medications were the migraine 
drug rizatriptan, and a compound containing Epsom salts (magnesium sulfate) that was prescribed 
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for constipation. The arterial blood gas machines (manufactured by Roche Global and IL Werfen) 
available to the authors did not have the capacity to measure SulfHb; the local Clinical Chemistry 
central laboratory was not able to perform spectrophotometry of haemoglobin. A Clinical Diagnostic 
Biotechnology start-up company (MAPSciences) had advanced mass spectrometry technology that 
could rapidly analyse haemoglobin and was approached to undertake analysis of the patient’s blood 
to establish if SulfHb was detectable.  
2. Materials and Methods  
Patient samples were provided as dried blood spots on Guthrie cards and as citrated whole 
blood. The patient gave written consent for her case to be reported 
2.1. MALDI-ToF MS of Globins for Aberrant Forms and Adducts 
To analyse whole blood samples for globin defects, 1 µL of citrated whole blood was first diluted 
in 500 µL, 1000 µL and 2000 µL of mass spectral grade distilled deionised water (ddH20) (ROMIL 
Ltd., Waterbeach, Cambridgeshire, UK). Alternatively, dried whole blood spots were punched with 
a 4 mm diameter circular hole punch from the center of Guthrie cards. The circular sample was then 
soaked in 4 mL of ddH20 for 2 hrs and further diluted twice by doubling dilution in ddH20. Matrix-
assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-ToF MS) sample slide 
plates were pre-coated with 1 µl of sinapinic acid (SA) at 10 mg/mL dissolved in 1:2 0.1% 
trifluoroacetic acid (TFA) and acetonitrile (Sigma Aldrich, Gillingham, Dorset, UK) and were allowed 
to air dry. One µL of diluted sample was then placed on a well and an additional 1 µL of a matrix 
was added on a wet sample well. The sample-matrix mixture was left to air dry and form crystals. 
This sample-matrix mixture was analysed on the Shimadzu 8020 clinical Linear MALDI ToF mass 
spectrometer that we optimised for analysis at 7000–17000 m/z. MALDI was internally calibrated 
with a singly and doubly charged Apomyoglobin (Sigma-Aldrich) protein standard [3]. 
 
Figure 2. Illustration of lysis of red blood cells by adding whole blood to distilled water, resulting in 
hemoglobin release, which dissociates into free alpha and beta globin protein chains, along with free 
heme. These are then resolved simply by matrix-assisted laser desorption ionization time-of-flight 
(MALDI-ToF) mass spectrometry, thus allowing for the relative quantification of variants and adducts 
for clinical diagnostic purposes. 
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2.2. Visible Light Absorption Spectral Analysis of Patient Whole Blood 
A total of 20 µL of whole blood samples were lysed in 2 ml of ddH2O. Due to the loss of 
quaternary structure to free subunits and the release of heme moieties from the globin protein chains, 
not only does this cause red cell lysis but also hemoglobin denaturation. At a dilution of 1/100, the 
main visible color is due to the abundant heme moieties. Visible spectral absorption was measured 
at 10 nm intervals between 500 and 700 nm, blanking at each wavelength against pure ddH2O. 
Spectral absorption was normalized against the peak absorption at 530nm to correct for variation in 
the total Hb concentration of individual samples and hence permit direct plot comparisons. 
 
Figure 3. Absorption spectra of hemoglobin samples. Panel (A): the patient and a female (F) and male 
(M) control sample; the arrow marks an increased absorption peak at 620 nm. Panel (B): the patient’s 
sample on admission, pre-transfusion, and post-transfusion compared to the control sample; the 
double arrow marks the absorption peak at 620 nm seen in all patient samples. 
2.3. MALDI-TOF MS of Blood for Heme Adducts. 
The control blood samples, M and F, along with the patient’s blood samples at presentation 
immediately prior to transfusion, post transfusion, and 1 month after magnesium sulfate ingestion 
was halted were analysed. As described above, 1 µL of whole blood, or dried blood spots soaked in 
ddH2O, at a dilution of 1 in 2000 was subjected to MALDI-ToF mass spectrometry. MALDI–ToF 
plates were pre-coated with 1 µL of alpha-cyano-4-hydroxycinnamic acid (CHCA) (Sigma-Aldrich, 
Bournemouth, Dorset, UK.) at a concentration of 20 mg/mL dissolved in 1:2 0.1% TFA and 
Acetonitrile, which was allowed to dry to crystals. A total of 1 µL of the diluted patient sample was 
added, and, before completely drying, another 1 µL of CHCA was added. After the sample matrix 
mix had completely dried to crystals, this sample was analysed on the Shimadzu 8020 clinical Linear 
MALDI ToF mass spectrometer, which was optimized for analysis at 500–700 m/z. MALDI was 
internally calibrated with a singly and doubly charged bradykinin 1–7 fragment (Sigma-Aldrich, ) 
protein standard. 
3. Results 
The addition of whole blood to ddH2O at a dilution of 1 in 2000 not only causes red cell lysis but 
also the dissociation of hemoglobin into free heme and free alpha and beta globins. Furthermore, as 
these are the most abundant proteins in lysed blood by more than an order of magnitude, all other 
molecules are effectively diluted out and these red cell components dominate mass spectral analysis 
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(Figure 2). Sinapinic acid as a matrix preferentially ionizes large proteins and was optimised for 
globin analysis as previously described [3,4]. The spectral analysis of the patient’s globin at 
presentation revealed no alteration to the globin proteins.  
As a relatively large amount of citrated blood had been provided, 2 mls of lysed blood was also 
examined by UV/visible spectroscopy. Two control samples were analysed (one male (control M) and 
a female (control F) with normal Hb) along with three of the patient’s samples (at presentation, 
immediately prior to transfusion, and post-transfusion). The expected absorption pattern is two 
major peaks at 550 nm (OxyHb) and 670–680 nm (DeoxyHb). A comparison of the patient’s admission 
sample (A) against the control (M and F) spectra shows a large increase in absorption from 600 to 700 
nm in the patient’s sample, with a minor maxima/peak at 620 nm (arrowed) (see Figure 3A). 
 
Figure 4. MALDI-ToF mass spectra of patient’s lysed blood demonstrating heme and heme adducts 
pre- (panel A) and post-transfusion (panel B). Positions of heme plus sulfur, sulfur monoxide and 
sulfur dioxide are indicated by the blue arrows. * indicate satellite peaks corresponding to addition 
of 1 and 2 m/z to the heme-adduct mass. This is probably due to additional hydrogen atoms. Ψ 
indicates peaks corresponding to unknown molecules present in the lysed RBCs but significantly 
abundant at 1 in 1000 dilution.  
A MALDI-ToF mass spectral analysis of the samples in the CHCA matrix revealed heme 
moieties at 618 m/z. However, in the patient’s samples prior to transfusion, additional peaks 
corresponding to heme-sulfur adduct (plus or minus hydrogen, −SH) at 652 m/z, heme-sulfur 
monoxide (plus or minus hydrogen, −SOH) at 668–670 m/z, and sulfur dioxide (plus or minus 
hydrogen, SO2H) at 683–685 m/z (see Figure 4A). A higher resolution image is shown in supplemental 
Figure S1. These heme-sulfur adduct peaks were greatly reduced in comparison in the control 
samples and had largely disappeared in the patient’s repeat blood samples post-transfusion (see 
Figure 4B) and after she had stopped taking magnesium sulfate (see Table 1).  
Table 1. Percentage of heme and sulfated adducts in blood samples. 
SAMPLE 
Heme (618 
m/z) 
Heme+ 
S(H) 
(652 m/z) 
Heme+ 
S0(H) 
(669 m/z) 
Heme+ 
S02(H) 
(684 m/z) 
Male control  
95.3% 
 
2% 
 
2% 
 
0.7% 
Female control  
96.3% 
 
1.4% 
 
1.4% 
 
0.9% 
Patient at presentation     
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57.1% 8.8% 18.7% 15.4% 
Patient pre-transfusion  
45.5% 
 
18.2% 
 
21.8% 
 
14.5% 
Patient post-Transfusion  
89.6% 
 
3.8% 
 
3.4% 
 
3.2% 
Patient after cessation of magnesium 
sulfate treatment 
 
94% 
 
1.1% 
 
3.5% 
 
1.2% 
4. Discussion 
This case report illustrates the diagnostic difficulties encountered when SulfHb is present and 
the potential for confusion with MetHb. For this reason, SulfHb has also been known as 
‘pseudomethemoglobinemia’ [5]. As demonstrated here, patients typically present with persistently 
low oxygen saturation on pulse oximetry, normal oxygen partial pressure on arterial blood gas 
sampling [6,7]. In addition, repeated error messages can be returned by arterial blood gas machines 
designed to differentiate Methemoglobin. Knowledge of the available arterial blood gas co-oximetry 
methodology is essential if the presence of SulfHb is suspected, as there is variation in the ability to 
detect the SulfHb species between co-oximeters produced by different manufacturers—many are 
unable to differentiate SulfHb and MetHb due to overlap between their absorption spectra [8]. Most 
notably, SulfHb shares a similar absorption peak with MetHb at 630 nm, and thus a SulfHb may be 
reported by some systems as a MetHb. Additionally, drugs with both oxidant properties and sulfur 
groups can produce both SulfHb and MetHb. Gas chromatography has, until now, been considered 
the ‘gold standard’ technique for the identification of SulfHb [9]. However, as seen in this case, it is 
frequently not readily available to the investigating clinicians. Other methods employed for 
establishing the presence of SulfHb are isoelectric focusing and measuring the absorption of light of 
blood at 630 nm after the addition of cyanide or dithionate (which diminishes absorption by MetHb, 
but not by SulfHb). The latest generation of co-oximeters are designed to measure SulfHb in addition 
to MetHb, but these are not, as yet, in widespread use in the authors’ country. The mass spectroscopic 
technique MALDI-ToF MS was employed after examination visible light absorption spectra of the 
patient’s whole blood in a commercial lab conclusively demonstrated the presence of SulfHb. 
Furthermore, this technique successfully identified the presence of sulfur, sulfur monoxide and 
dioxide bound to heme moieties (rather than hydrogen sulphide), and their reduction following 
exchange transfusion. The the receipt of a whole blood sample to results took no more than twenty 
minutes. 
SulfHb is a rare complication of exposure of heme groups to sulfur. It causes the irreversible 
bonding of sulfur to the heme moiety, with resultant cyanosis as SulfHb does not bind oxygen. The 
clinical presentation is similar to that of MetHb, but it does not respond to treatment with methylene 
blue or ascorbic acid. However, the presence of SulfHb decreases the oxygen affinity of unaffected 
hemoglobin, with left-shift of the oxygen-dissociation curve and improved oxygen delivery to tissues, 
while the converse is true of MetHb; SulfHb thus tends to be associated with milder clinical 
symptoms than MetHb [10]. There is no specific treatment for SulfHb, and in most cases described to 
date, clinical symptoms are mild. Where treatment is felt to be required, exchange transfusion is the 
intervention of choice as it can reduce the proportion of SulfHb given that, once binding of sulfur to 
hemoglobin has occurred, it will last for the 120-day lifespan of the erythrocyte. This clinical 
management strategy is reflected in the measured oxygen saturations in this patient (see Figure 5). 
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Figure 5. Plot of patient’s oxygen saturation values (blue line) from presentation and during 
treatment. Red arrows indicate interventions: First exchange transfusion and second cessation of 
ingestion of magnesium sulfate. 
From an analytical stand point, true methemoglobin is unlikely to be revealed by this direct 
MALDI-ToF mass spectrometry approach, as, in this condition, the heme has been oxidized from the 
normal ferrous (Fe2+) to the ferric state (Fe3+) and has merely lost an electron, which is a negligible 
mass difference.  
Gas chromatography mass spectrometry has been reported to differentiate both SulfHb and 
MetHb from normal heme and this is because separation by this technique is first chromatographic, 
as a function of column absorption via differences inherent in molecular charge/polarity, and then 
detection is characterised by mass. However, the technique requires considerable sample pre-
preparation (e.g., precipitation of heme from the blood followed by derivatisation), is technically 
demanding, time consuming, and expensive. Within the clinical setting, optical absorption 
spectrometry is bedside, rapid, and an inexpensive methodology to determine MetHb. As 
demonstrated here, MALDI-ToF mass spectrometry is extremely rapid, technically straight forward, 
negligible in analysis reagent costs, and reveals an adduct to heme that causes a change in mass, such 
as sulfur and its associated molecular species.  
Interestingly, the “Heme-Sulfo” peaks (labelled in Figure 4) are accompanied by satellite peaks 
varying in mass by precisely 1 and 2 m/z (labelled with an *). In SulfHb, gaseous hydrogen sulfide or 
sulfur dioxide bind to the heme of haemoglobin. Although some reports have suggested that the 
sulfur molecules binds to the porphyrin [10], there is no analytical evidence to support this, and 
earlier chemists suggest that the interaction is probably via strong ionic, even covalent, linkage to the 
caged Fe ion [11]. Nevertheless, this results in a significant increase in mass, the difference 
corresponding to atomic sulfur and oxygen or hydrogen, or both. If chelated to Fe, and not the 
porphyrin groups of the heme, hydrogen can also bind to the Fe-S complexes and the additional 
satellite peaks seen in this case may represent hydrogen joining the Heme Fe-S, Heme Fe-SO, and Fe-
S02 complexes, i.e., FeSH/FeSH2, FeOH/FeSOH2, and FeSO2H/FeSO2H2, the further increase in mass 
being 1 and 2 m/z. (see supplemental Figure S1).  
We have also noted that heme, upon MALDI-ToF analysis, is often accompanied by satellite 
peaks of an increased mass of 1 and 2 m/z presumably via similar interactions. This gives rise to the 
intriguing possibility that the MALDI-ToF MS technique described may possibly be able to 
distinguish MetHb by virtue of the fact that the ratio of the 1 and 2 m/z satellite peaks will be different 
depending on the patient heme being in the normal ferrous (Fe2+) or aberrant ferric (Fe3+) state. Further 
studies are ongoing. 
For speed and ease of analysis, there is no extraction and a simple lysis, dilute, and shoot was 
employed. Although haemoglobin is the most abundant molecule in blood, many other components 
are still seen and one in 1000 or greater dilutions. These are most probably blood group antigens and 
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components of the red blood cell cytoskeleton. Four such minor peaks resolve on the mass spectra 
close to that of the sulf-heme adducts (labelled with a Ψ) at 658, 672, 689, and 708 m/z, but are 
currently unidentified.  
5. Conclusions 
To the authors’ knowledge, this is the first report using MALDI-TOF MS in the detection of 
SulfHb. Many previous cases of SulfHb described in the literature are thought to relate to hydrogen 
sulphide causing SulfHb, often in the context of bacterial overgrowth in the gastrointestinal tract (for 
example, in patients with severe constipation), and by poisoning with agricultural chemicals. 
MALDI-ToF MS enabled the specific identification of sulfur dioxide rather than hydrogen sulphide 
bound to heme in this patient’s case, and this assisted with establishing the most likely source of 
SulfHb in this patient, who both suffers from severe constipation, and was also prescribed drugs 
containing sulfur groups. MALDI-ToF MS is a highly specific and rapid methodology for the 
investigation of dyshemoglobin molecules and should be considered as an alternative to gas 
chromatography for the definitive diagnosis of SulfHb.  
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Patient 
blood sample profile at presentation  
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